SLC5A2 and type 1 diabetes mellitus: The only drugs that have been convincingly shown to be able to reduce the risk of hospitalization and mortality in HFpEF are SGLT2-is [14,26,27], whose use in T1D has been severely restricted in multiple countries [28,29] due to their increased risk of euglycemic ketoacidosis.